Commentary

Video

Dr Li on the Rationale of the MoonRISe-1 Trial in NMIBC

Author(s):

Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).

Roger Li, MD, a genitourinary oncologist at Moffitt Cancer Center, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820) examining TAR-210 vs intravesical chemotherapy in patients with non–muscle-invasive bladder cancer.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Terence W. Friedlander, MD
Terence W. Friedlander, MD
John K. Lee, MD, PhD
Guru P. Sonpavde, MD
Guru P. Sonpavde, MD
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB